GENMAB A/S GNMSF news, videos and press releases - Page 2
For more news please use our advanced search feature.
GENMAB A/S GNMSF - More news...
GENMAB A/S GNMSF - More news...
- Transactions in connection with share buy-back program
- Transactions in connection with share buy-back program
- Genmab Announces that Janssen has been Granted U.S. FDA Approval for RYBREVANT™ (amivantamab-vmjw) for Patients with Metastatic Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations
- Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX® (daratumumab) Subcutaneous (SC) Formulation for Patients with Newly Diagnosed Light-chain (AL) Amyloidosis
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Genmab Announces Abstracts Evaluating Products in Pipeline, Portfolio to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting and European Hematology Association (EHA) Congress
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Transactions in connection with share buy-back program
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Capital Increase in Genmab as a Result of Employee Warrant Exercise
- Transactions in connection with share buy-back program
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Genmab Announces Financial Results for the First Quarter of 2021
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Transactions in connection with share buy-back program
- Transactions in connection with share buy-back program
- Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2021
- Transactions in connection with share buy-back program
- Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
- Constitution of the Board of Directors in Genmab A/S and Grant of Restricted Stock Units and Warrants to Employees and a New Member of Management in Genmab
- Passing of Genmab A/S’ Annual General Meeting
- Transactions in connection with share buy-back program
- Genmab and Seagen Announce U.S. FDA Filing Acceptance for Priority Review of Tisotumab Vedotin Biologics License Application for Patients with Recurrent or Metastatic Cervical Cancer
- Transactions in connection with share buy-back program
- Genmab Announces European Marketing Authorization for Kesimpta® (ofatumumab) in Relapsing Multiple Sclerosis
- Genmab Files Annual Report with the U.S. Securities and Exchange Commission
- Transactions in connection with share buy-back program
- Transactions in connection with share buy-back program
- Transactions in connection with share buy-back program